383 related articles for article (PubMed ID: 18312775)
21. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy.
Jayatilleke I; Doolan A; Ingles J; McGuire M; Booth V; Richmond DR; Semsarian C
Am J Cardiol; 2004 May; 93(9):1192-4. PubMed ID: 15110224
[TBL] [Abstract][Full Text] [Related]
22. Can sudden cardiac death be prevented?
Maron BJ
Cardiovasc Pathol; 2010; 19(6):329-35. PubMed ID: 20378375
[TBL] [Abstract][Full Text] [Related]
23. [Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm and sustained ventricular tachycardia: a case report].
Kono K; Higashi T; Hara K; Mori S; Ito I; Shinbo G; Anzai R; Yagi H; Tamano K; Horinaka S; Matsuoka H
J Cardiol; 2001 Dec; 38(6):343-9. PubMed ID: 11806092
[TBL] [Abstract][Full Text] [Related]
24. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.
Cotiga D; Ehlert F; Sherrid M
Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():55-60. PubMed ID: 17162272
[TBL] [Abstract][Full Text] [Related]
25. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.
Payá E; Marín F; González J; Gimeno JR; Feliu E; Romero A; Ruiz-Espejo F; Roldán V; Climent V; de la Morena G; Valdés M
J Card Fail; 2008 Jun; 14(5):414-9. PubMed ID: 18514934
[TBL] [Abstract][Full Text] [Related]
26. Sudden death as a presenting symptom of hypertrophic cardiomyopathy: treatment with an implantable cardioverter defibrillator.
Talard P; Lévy S; Bonal J; Paganelli F; Bouchiat C; Cellarier G; Dussarat GV
Pacing Clin Electrophysiol; 1996 Aug; 19(8):1264-7. PubMed ID: 8865227
[TBL] [Abstract][Full Text] [Related]
27. [Detection and quantification of myocardial fibrosis in hypertrophic cardiomyopathy by contrast-enhanced cardiovascular magnetic resonance].
Pujadas S; Carreras F; Arrastio X; Leta R; Vila M; Subirana MT; Bayés-Genís A; Pons-Lladó G
Rev Esp Cardiol; 2007 Jan; 60(1):10-4. PubMed ID: 17288950
[TBL] [Abstract][Full Text] [Related]
28. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
[TBL] [Abstract][Full Text] [Related]
29. [Arrhythmias of primary hypertrophic cardiomyopathy].
Babuty D; Fauchier L; Nguyen D; Giraudeau C; Marie O; Fauchier JP; Cosnay P
Arch Mal Coeur Vaiss; 2003 Dec; 96 Spec No 7():7-15. PubMed ID: 15272516
[TBL] [Abstract][Full Text] [Related]
30. [Sudden cardiac death: can individual risk be predicted?].
Meinertz T; Hofmann T; Zehender M
Z Gesamte Inn Med; 1992 May; 47(5):181-8. PubMed ID: 1615727
[TBL] [Abstract][Full Text] [Related]
31. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator.
Maron BJ
Eur Heart J; 2000 Dec; 21(24):1979-83. PubMed ID: 11102243
[No Abstract] [Full Text] [Related]
32. [Cardiac arrest in the pediatric population].
Tavares A; Trigo C; Estrada J
Acta Med Port; 2008; 21(4):383-6. PubMed ID: 19094815
[TBL] [Abstract][Full Text] [Related]
33. A comprehensive approach to management of ventricular arrhythmias.
Kusumoto F
Cardiol Clin; 2008 Aug; 26(3):481-96, vii. PubMed ID: 18538192
[TBL] [Abstract][Full Text] [Related]
34. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm.
Lim KK; Maron BJ; Knight BP
J Cardiovasc Electrophysiol; 2009 Apr; 20(4):445-7. PubMed ID: 19054248
[TBL] [Abstract][Full Text] [Related]
35. Significance of appropriate defibrillator shock 3 hours and 20 minutes following implantation in a patient with hypertrophic cardiomyopathy.
Almquist AK; Hanna CA; Haas TS; Maron BJ
J Cardiovasc Electrophysiol; 2008 Mar; 19(3):319-22. PubMed ID: 17764447
[TBL] [Abstract][Full Text] [Related]
36. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy.
Harrigan CJ; Appelbaum E; Maron BJ; Buros JL; Gibson CM; Lesser JR; Udelson JE; Manning WJ; Maron MS
Am J Cardiol; 2008 Mar; 101(5):668-73. PubMed ID: 18308018
[TBL] [Abstract][Full Text] [Related]
37. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
[TBL] [Abstract][Full Text] [Related]
38. Risk assessment with cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
Gosling OE; Bellenger N; Spurrell P
Heart; 2009 Nov; 95(22):1843. PubMed ID: 19875370
[No Abstract] [Full Text] [Related]
39. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy.
Miller MA; Gomes JA; Fuster V
Nat Clin Pract Cardiovasc Med; 2007 Dec; 4(12):667-76. PubMed ID: 18033231
[TBL] [Abstract][Full Text] [Related]
40. Syncope and risk of sudden death in hypertrophic cardiomyopathy.
Spirito P; Autore C; Rapezzi C; Bernabò P; Badagliacca R; Maron MS; Bongioanni S; Coccolo F; Estes NA; Barillà CS; Biagini E; Quarta G; Conte MR; Bruzzi P; Maron BJ
Circulation; 2009 Apr; 119(13):1703-10. PubMed ID: 19307481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
